拜瑞妥-话题@MedSci

#拜瑞妥#

10篇内容 | 713人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1744143, encodeId=4c231e4414373, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=CONKO-011研究表明，与低分子量肝素相比，拜瑞妥®抗凝效果更优，肿瘤合并静脉血栓栓塞患者治疗满意度更高, objectType=article, longId=212554, objectId=e12f21255421, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12f21255421, replyNumber=0, likeNumber=34, createdTime=2021-08-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12f21255421, moduleTitle=CONKO-011研究表明，与低分子量肝素相比，拜瑞妥®抗凝效果更优，肿瘤合并静脉血栓栓塞患者治疗满意度更高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12f21255421)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744141, encodeId=24db1e4414161, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=肺栓塞新型口服抗凝药拜瑞妥®在华上市相关真实世界研究回顾, objectType=article, longId=121072, objectId=789e1210e23b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789e1210e23b, replyNumber=0, likeNumber=40, createdTime=2018-05-08, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789e1210e23b, moduleTitle=肺栓塞新型口服抗凝药拜瑞妥®在华上市相关真实世界研究回顾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789e1210e23b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744140, encodeId=a39a1e44140b7, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=肺栓塞新型口服抗凝药拜瑞妥在华上市, objectType=article, longId=116451, objectId=ccc411645118, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccc411645118, replyNumber=0, likeNumber=37, createdTime=2018-06-01, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccc411645118, moduleTitle=肺栓塞新型口服抗凝药拜瑞妥在华上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccc411645118)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744142, encodeId=9dbd1e4414279, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=拜耳/强生拜瑞妥® 预防静脉血栓栓塞, objectType=article, longId=94194, objectId=a0d894194ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d894194ec, replyNumber=0, likeNumber=54, createdTime=2018-02-07, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d894194ec, moduleTitle=拜耳/强生拜瑞妥® 预防静脉血栓栓塞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d894194ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744139, encodeId=05d61e441390c, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=CFDA批准拜耳Xarelto（拜瑞妥）用于非瓣膜性房颤患者，预防中风及治疗深静脉血栓（DVT）, objectType=article, longId=50253, objectId=1f5a50253da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f5a50253da, replyNumber=0, likeNumber=34, createdTime=2015-06-07, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f5a50253da, moduleTitle=CFDA批准拜耳Xarelto（拜瑞妥）用于非瓣膜性房颤患者，预防中风及治疗深静脉血栓（DVT）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f5a50253da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744137, encodeId=0c441e4413748, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA委员会否决, objectType=article, longId=29560, objectId=299929560b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=299929560b7, replyNumber=0, likeNumber=34, createdTime=2014-01-30, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=299929560b7, moduleTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA委员会否决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=299929560b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744138, encodeId=45321e441388b, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA拒绝, objectType=article, longId=30710, objectId=226d30e1046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=226d30e1046, replyNumber=0, likeNumber=34, createdTime=2014-04-03, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=226d30e1046, moduleTitle=强生拜瑞妥（Xarelto）ACS适应症遭FDA拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=226d30e1046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744136, encodeId=ad7c1e44136b5, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=FDA对强生拜瑞妥（Xarelto）ACS适应症持谨慎态度, objectType=article, longId=29502, objectId=cad6295023e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cad6295023e, replyNumber=0, likeNumber=34, createdTime=2014-09-29, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cad6295023e, moduleTitle=FDA对强生拜瑞妥（Xarelto）ACS适应症持谨慎态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cad6295023e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744134, encodeId=2ea61e441342b, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=拜耳向欧盟提交拜瑞妥（Xarelto）上市许可申请, objectType=article, longId=5430, objectId=675254302e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=675254302e, replyNumber=0, likeNumber=36, createdTime=2012-08-28, rootId=0, userName=wincls, userId=057935300880, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=675254302e, moduleTitle=拜耳向欧盟提交拜瑞妥（Xarelto）上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=675254302e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744135, encodeId=1cd21e4413507, content=<a href='/topic/show?id=8a5d56256fb' target=_blank style='color:#2F92EE;'>#拜瑞妥#</a>, objectTitle=强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝, objectType=article, longId=6484, objectId=92836484f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92836484f5, replyNumber=0, likeNumber=41, createdTime=2012-11-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92836484f5, moduleTitle=强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92836484f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

拜瑞妥

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#拜瑞妥#

CONKO-011研究表明，与低分子量肝素相比，拜瑞妥®抗凝效果更优，肿瘤合并静脉血栓栓塞患者治疗满意度更高

2021-08-16

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

肺栓塞新型口服抗凝药拜瑞妥®在华上市相关真实世界研究回顾

2018-05-08

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

肺栓塞新型口服抗凝药拜瑞妥在华上市

2018-06-01

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

拜耳/强生拜瑞妥® 预防静脉血栓栓塞

2018-02-07

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

CFDA批准拜耳Xarelto（拜瑞妥）用于非瓣膜性房颤患者，预防中风及治疗深静脉血栓（DVT）

2015-06-07

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

强生拜瑞妥（Xarelto）ACS适应症遭FDA委员会否决

2014-01-30

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

强生拜瑞妥（Xarelto）ACS适应症遭FDA拒绝

2014-04-03

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

FDA对强生拜瑞妥（Xarelto）ACS适应症持谨慎态度

2014-09-29

wincls (审核中...)

前往app查看评论内容

#拜瑞妥#

拜耳向欧盟提交拜瑞妥（Xarelto）上市许可申请

2012-08-28

zhaojie88 (审核中...)

前往app查看评论内容

#拜瑞妥#

强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝

2012-11-28

科室
- - 订阅+
  - 更多科室
工具
服务